Physician profile
Joseph Schlecht
NPI 1801895024
$3,368.35
in general payments reported to CMS, 2019-2025
31 companies · $13.66 in 2025
The $13.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $170 · 2021: $659 · 2022: $471 · 2023: $779 · 2024: $1,044 · 2025: $13.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $983.90 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $302.87 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $255.91 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $244.61 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.92 | 2021-2024 | Jardiance |
| Abbvie INC. | $215.19 | 2020-2024 | |
| Abbott Laboratories | $175.58 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $109.47 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $98.45 | 2021-2024 | |
| Glaxosmithkline, LLC. | $87.26 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $64.96 | 2022 | |
| Therapeuticsmd, INC. | $55.19 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $54.42 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $43.72 | 2019 | |
| Alk-Abello, INC | $42.79 | 2023-2024 | Ragwitek, Grastek, Odactra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.53 | 2019-2020 | |
| Baxter Healthcare | $36.54 | 2019-2023 | Hillrom - Life 2000 Ventilation System |
| Phathom Pharmaceuticals, INC. | $34.77 | 2024 | Voquezna |
| Antares Pharma, INC. | $34.03 | 2024 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $29.33 | 2023 | |
| Smith+Nephew, INC. | $28.12 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $26.86 | 2024 | Rexulti |
| Boston Scientific Corporation | $23.94 | 2019 | |
| Hologic Sales and Service, LLC | $23.25 | 2021 | |
| Amarin Pharma, INC. | $23.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.87 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.62 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $17.27 | 2021 | |
| Dexcom, INC. | $15.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.54 | 2022 | |
| Currax Pharmaceuticals LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schlecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.